ProQR Therapeutics upgraded to Strong Buy from Outperform at Raymond James

Raymond James upgraded ProQR Therapeutics (PRQR) to Strong Buy from Outperform with a price target of $14, up from $6. The firm cites the recent successful clinical translation of RNA editing for the upgrade. The analyst has “even higher conviction now” in clinical translation of ProQR’s lead program AX-0810, which edits NTCP for treatment of cholestatic diseases. Raymond James notes that ProQR expects to provide additional preclinical data for AX-0810 related to the selected candidate and its delivery modality as well as pre-clinical data for AX-1412 in cardiovascular disease by the end of 2024.